Thursday, April 25, 2013 10:28:03 AM
OTC Fish Oil Supplement Math doesn't add up
Before being put on a 4g daily dose of Vascepa, I used to take a 1200 mg OTC Fish Oil Supplement.
Of the 1200mg, the amount of Omega-3's in the capsule was 360 mg.
Contained in the 360 mg of Omega-3's were EPA, DHA, and 'other Fatty Acids'.
There's no breakdown of the ratio of EPA/DHA on the product label, but if you assume that 50% of the 360 mg of the Omega-3 content is EPA, you get 180 mg of EPA.
To get the same amount of EPA on the OTC supplement that you get in a 4g daily dose of Vascepa, you would have to take:
4000mg/180 mg = 22.22 x 1200 mg OTC Fish Oil Capsules per day
Each bottle of the OTC 1200 mg Fish Oil supplement contains 100 capsules, which means that a bottle of this quantity would last 4.5 days, which means one would have to take 6.67 bottles of 100 capsules 1200 mg OTC supplement per month to get the same amount of EPA contained in 120 Vascepa capsules.
Vascepa wins hands down.
Before being put on a 4g daily dose of Vascepa, I used to take a 1200 mg OTC Fish Oil Supplement.
Of the 1200mg, the amount of Omega-3's in the capsule was 360 mg.
Contained in the 360 mg of Omega-3's were EPA, DHA, and 'other Fatty Acids'.
There's no breakdown of the ratio of EPA/DHA on the product label, but if you assume that 50% of the 360 mg of the Omega-3 content is EPA, you get 180 mg of EPA.
To get the same amount of EPA on the OTC supplement that you get in a 4g daily dose of Vascepa, you would have to take:
4000mg/180 mg = 22.22 x 1200 mg OTC Fish Oil Capsules per day
Each bottle of the OTC 1200 mg Fish Oil supplement contains 100 capsules, which means that a bottle of this quantity would last 4.5 days, which means one would have to take 6.67 bottles of 100 capsules 1200 mg OTC supplement per month to get the same amount of EPA contained in 120 Vascepa capsules.
Vascepa wins hands down.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
